Acambis and Berna are developing HolaVax-Typhoid, a single-dose, live attenuated oral vaccine for the potential prophylaxis of typhoid. A phase II trial was successfully completed in January 1999, and in September 2002, Acambis announced that a bridging trial was planned for the first half of 2003 to confirm that the vaccine produced by Berna was equivalent to the typhoid vaccine that had been studied previously.
All Keywords